(Q54070928)

24 May 2018

title

In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria. (English)

1 reference

24 May 2018

1 reference

Malathum K

1

1 reference

24 May 2018

Singh KV

series ordinal

2

1 reference

24 May 2018

Murray BE

series ordinal

3

1 reference

24 May 2018

publication date

1 October 1999

1 reference

24 May 2018

Diagnostic Microbiology and Infectious Disease

published in

1 reference

24 May 2018

volume

35

1 reference

24 May 2018

issue

2

1 reference

24 May 2018

page(s)

127-133

1 reference

24 May 2018

National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986-April 1998, issued June 1998

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2899%2900065-6

7 January 2021

10.1016/S0732-8893(99)00065-6

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018